ArticleGene therapy2005
Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Live long and active: Polypeptide-mediated assembly of antibody variable fragments.Advanced drug delivery reviews · 2020Pooled it
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Review
- Three-dimensional tumor cell cultures employed in virotherapy research.Oncolytic virotherapy · 2018Review
- Designing and building oncolytic viruses.Future virology · 2017Review
- ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells.Journal of virology · 2015Article
- Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Human gene therapy · 2014Review
- Retargeting of viruses to generate oncolytic agents.Advances in virology · 2012Article
- Non-human viruses developed as therapeutic agent for use in humans.Reviews in medical virology · 2011Review
- Identification of host factors involved in coronavirus replication by quantitative proteomics analysis.Proteomics · 2011Article
- Dynamics of coronavirus replication-transcription complexes.Journal of virology · 2010Article
- Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma.Journal of virology · 2009Article
- Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.Oncogene · 2008Article
- Mouse hepatitis coronavirus RNA replication depends on GBF1-mediated ARF1 activation.PLoS pathogens · 2008Article
- Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein.Journal of virology · 2008Article
- Intracellular restriction of a productive noncytopathic coronavirus infection.Journal of virology · 2008Article
- Expression of anti-tumor recombinant IgG- and IgE-like genes in eukaryotic cells.Russian journal of genetics · 2008Article
- Gene therapy in The Netherlands: highlights from the Low Countries.The journal of gene medicine · 2007Review
- The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins.The Journal of antimicrobial chemotherapy · 2007Article
- Oncolytic viruses in cancer therapy.Cancer letters · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the potential of using non-human coronaviruses for cancer therapy, we first established their ability to kill human tumor cells. We found that the feline infectious peritonitis virus (FIPV) and a felinized murine hepatitis virus (fMHV), both normally incapable of infecting human cells, could rapidly and effectively kill human cancer cells artificially expressing the feline coronavirus receptor aminopeptidase N. Also 3-D multilayer tumor spheroids established from such cells were effectively eradicated. Next, we investigated whether FIPV and fMHV could be targeted to human cancer cells by constructing a bispecific single-chain antibody directed on the one hand against the feline coronavirus spike protein--responsible for receptor binding and subsequent cell entry through virus-cell membrane fusion--and on the other hand against the human epidermal growth factor receptor (EGFR). The targeting antibody mediated specific infection of EGFR-expressing human cancer cells by both coronaviruses. Furthermore, in the presence of the targeting antibody, infected cancer cells formed syncytia typical of productive coronavirus infection. By their potent cytotoxicity, the selective targeting of non-human coronaviruses to human cancer cells provides a rationale for further investigations into the use of these viruses as anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.